WHO recommends a clinical trial of Ebola vaccine against Bundibugyo virus
Why Ervebo is being considered The advisory group’s recommendation is significant because Ervebo was developed specifically against Ebola virus disease caused by the Ebola Zaire virus, rather than the Bundibugyo virus.
Safety concerns According to WHO, the advisory group found no identified safety concerns with the use of Ervebo among contacts of confirmed cases during a Bundibugyo virus disease outbreak.
READ ALSO: WHO raises alarm as DR Congo’s Ebola outbreak surpasses 3,600 cases However, the experts stressed that the vaccine’s effectiveness against Bundibugyo virus disease and its ability to prevent transmission have not been established.
This is a summary of the original articles listed below. Always read the source articles for the full context. GhanaSummary does not create or modify the news — we summarise and link to original publishers.
